Enables mRNA 3'-UTR binding activity and mRNA base-pairing translational repressor activity. Involved in several processes, including negative regulation of angiogenesis; negative regulation of smooth muscle cell migration; and regulation of gene expression. Acts upstream of or within negative regulation of gene expression. Located in extracellular exosome. Implicated in hepatocellular carcinoma. Biomarker of arteriovenous malformation; hepatoblastoma; hepatocellular carcinoma; metabolic dysfunction-associated steatotic liver disease; and osteoarthritis.
[Tretinoin co-treated with Phenylbutyrates co-treated with 1-hydroxy-2-oxo-3 and 3-bis(2-aminoethyl)-1-triazene] results in increased expression of MIR34A mRNA
[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of MIR34A mRNA and Melatonin inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of MIR34A mRNA]
[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of MIR34A mRNA and Melatonin inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of MIR34A mRNA]
Benzo(a)pyrene promotes the reaction [Dibutyl Phthalate results in decreased expression of MIR34A mRNA] and Dibutyl Phthalate promotes the reaction [Benzo(a)pyrene results in decreased expression of MIR34A mRNA]
betanin inhibits the reaction [Cisplatin results in increased expression of MIR34A mRNA] and Pentoxifylline inhibits the reaction [Cisplatin results in increased expression of MIR34A mRNA]
[[MIR34A binds to MAGEA12 3' UTR] which results in decreased expression of MAGEA12 protein] which results in increased susceptibility to Cisplatin more ...
MIR34A mRNA inhibits the reaction [crocin results in increased activity of CASP3 protein] and MIR34A mRNA inhibits the reaction [crocin results in increased expression of PTPN4 protein]
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIR34A mRNA
Gallic Acid affects the reaction [[Dietary Fats co-treated with Dust] affects the expression of MIR34A mRNA] and Gallic Acid inhibits the reaction [Dust results in increased expression of MIR34A mRNA]
[Lithium Chloride results in increased abundance of Lithium] inhibits the reaction [Paraquat results in increased expression of MIR34A mRNA] and [Lithium Chloride results in increased abundance of Lithium] which results in decreased expression of MIR34A mRNA
[Lithium Chloride results in increased abundance of Lithium] inhibits the reaction [Paraquat results in increased expression of MIR34A mRNA] and [Lithium Chloride results in increased abundance of Lithium] which results in decreased expression of MIR34A mRNA
[Lithium Chloride results in increased abundance of Lithium] inhibits the reaction [Paraquat results in increased expression of MIR34A mRNA] and [Lithium Chloride results in increased abundance of Lithium] which results in decreased expression of MIR34A mRNA
[[MIR34A binds to MAGEA12 3' UTR] which results in decreased expression of MAGEA12 protein] which results in increased susceptibility to Mitomycin more ...
Nicotinamide Mononucleotide inhibits the reaction [MIR34A mRNA inhibits the reaction [NAMPT protein results in increased chemical synthesis of NAD]] more ...
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIR34A mRNA
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIR34A mRNA
[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of MIR34A mRNA and Melatonin inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of MIR34A mRNA]
Plant Extracts inhibits the reaction [sodium arsenite results in increased expression of MIR34A mRNA] and TRP53 protein promotes the reaction [Plant Extracts inhibits the reaction [sodium arsenite results in increased expression of MIR34A mRNA]]
MIR34A mRNA inhibits the reaction [titanium dioxide results in increased expression of BCL2 mRNA] and MIR34A mRNA inhibits the reaction [titanium dioxide results in increased expression of BCL2 protein]
MicroRNA-31 activates the RAS pathway and functions as an oncogenic MicroRNA in human colorectal cancer by repressing RAS p21 GTPase activating protein 1 (RASA1).
Elevated circulating microRNA-210 levels in patients with hereditary hemorrhagic telangiectasia and pulmonary arteriovenous malformations: a potential new biomarker.
Developmental Delay and additional significant developmental and morphological phenotypes referred for genetic testing [RCV000051795]|Developmental delay and additional significant developmental and morphological phenotypes referred for genetic testing [RCV000051795]|See cases [RCV000051795]
Developmental Delay and additional significant developmental and morphological phenotypes referred for genetic testing [RCV000052038]|Developmental delay and additional significant developmental and morphological phenotypes referred for genetic testing [RCV000052038]|See cases [RCV000052038]
Developmental Delay and additional significant developmental and morphological phenotypes referred for genetic testing [RCV000053727]|Developmental delay and additional significant developmental and morphological phenotypes referred for genetic testing [RCV000053727]|See cases [RCV000053727]
Developmental Delay and additional significant developmental and morphological phenotypes referred for genetic testing [RCV000053730]|Developmental delay and additional significant developmental and morphological phenotypes referred for genetic testing [RCV000053730]|See cases [RCV000053730]
Developmental Delay and additional significant developmental and morphological phenotypes referred for genetic testing [RCV000053713]|Developmental delay and additional significant developmental and morphological phenotypes referred for genetic testing [RCV000053713]|See cases [RCV000053713]
Developmental Delay and additional significant developmental and morphological phenotypes referred for genetic testing [RCV000053716]|Developmental delay and additional significant developmental and morphological phenotypes referred for genetic testing [RCV000053716]|See cases [RCV000053716]
